Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Liver Neoplasms 2Neuroendocrine Tumors 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 5Magnetic Resonance Spectroscopy 5pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1fludarabine phosphate 1exemestane 1decitabine and cedazuridine drug combination 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Tumors × Sirtuins × Clear all
NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Emory University

Phase 1 Completed
13 enrolled
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡